Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep628 | Pituitary and Neuroendocrinology | ECE2020

Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

Toth Miklos , Gordon Murray , Doknic Mirjana , Mezosi Emese , Randeva Harpal , Marmon Tonya , Fowler Kim , Luo Rosa , Monahan Michael , Madan Ajay , Ferrara-Cook Chris , Scott Struthers R. , Krasner Alan

Peptide long-acting somatostatin receptor ligands (SRLs) are a first line medical treatment for acromegaly but are not efficiently absorbed when delivered orally. Years of injections with SRLs are associated with variable dose delivery, injection site reactions, and excessive life burden. Paltusotine (CRN00808) is a nonpeptide small molecule somatostatin type 2 (sst2) receptor agonist with high oral bioavailability (70%) and a 42–50 hour terminal elimination half-life in...

ea0031p57 | Clinical practice/governance and case reports | SFEBES2013

Initiation and maintenance of mitotane as adjuvant therapy for adrenocortical cancer: a single centre experience

Whitelaw Benjamin , Mustafa Omar , Coskeran Patsy , Prague Julia , Kordbacheh Tiana , Lewis Dylan , Diaz-Cano Salvador , Sherwood Roy , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Mitotane is an adrenolytic chemotherapy, currently accepted as first line adjuvant therapy in adrenocortical carcinoma. Mitotane has a narrow therapeutic window. Serum levels of >14 mg/l are required to achieve a cytotoxic effect and levels of >20 mg/l are potentially toxic. There are two strategies for mitotane initiation: a low-dose regimen (3 g) and a high-dose regimen (increase to 6g/day over 4 days and reduce to 4.5 g/day after 10 days).<p class="...

ea0031p158 | Neoplasia, cancer and late effects | SFEBES2013

Pituitary metasases: patients presenting with cranial nerve palsies and diabetes insipidus: a single centre experience

Salaris Paola , Kordbacheh Tiana , Whitelaw Ben , Mustafa Omar , Visca Anna , Thomas Nick , Bullock Peter , Barazi Sinan , Landau David , King Andrew , Hampton Timothy , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Pituitary metastases are a rare complication of systemic malignancy. The most common presentations of pituitary masses include visual field defects, headaches, and hypopituitarism, but cranial nerve palsies and diabetes insipidus are also recognised although unusual. We aimed to determine if these were more frequently associated with pituitary metastasis.Methods: We conducted a review of 944 patients undergoing pituitary surgery from a teachi...

ea0031p207 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2013

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity

Kahal Hassan , Aburima Ahmed , Ungvari Tamas , Rigby Alan , Dawson Alison , Coady Anne-Marie , Vince Rebecca , Ajjan Ramzi , Kilpatrick Eric , Naseem Khalid , Atkin Stephen

Introduction: Previous studies investigating cardiovascular (CV) risk in obese women with polycystic ovary syndrome (PCOS) have been potentially confounded by not adequately accounting for body weight.Objective: To assess if PCOS increases CV risk independently in young obese women by examining carotid intima-media wall thickness (cIMT) and platelet function.Design: A cross-sectional study comparing women with PCOS (n=21) ...

ea0031p257 | Pituitary | SFEBES2013

Endocrine remission of Cushing's disease after endoscopic trans-sphenoidal surgery: Retrospective review of a single centre experience

Kennard Devon , Whitelaw Ben , Dworakowska Dorota , Thomas Nick , Barazi Sinan , Bullock Peter , King Andrew , Hampton Tim , Sherwood Roy , Buchanan Charles , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Cushing’s disease is caused by corticotroph tumours of the pituitary gland and the standard first-line treatment is trans-sphenoidal surgery. Published data from other centres describes post-operative endocrine remission achieved in 50–90% of cases.Table 1 Remission (cortisol <50)Cortisol (50–150 nmol/l)<td alig...

ea0028p148 | Neoplasia, cancer and late effects | SFEBES2012

Radiological diagnosis frequently precedes clinical suspicion and biochemical confirmation in phaeochromocytoma: a pilot series

Prague Julia , Lewis Dylan , Kane Pauline , Vivian Gill , Whitelaw Benjamin , Ramasamy Shamin , Vincent Royce , Schulte Klaus-Martin , McGregor Alan , Aylwin Simon

Background: Kopetschke et al. (2009) suggested that nearly thirty per-cent of adrenal/extra-adrenal phaeochromocytoma were found incidentally1. However, they included cases from 1973 to 2007, whereas in the modern era CT and MR investigations are requested more frequently and earlier in the diagnostic algorithm.Methods: We report a pilot series of consecutive referrals to a tertiary centre for adrenal and extra-adrenal phaeochromocytoma from July ...

ea0021p25 | Bone | SFEBES2009

Extra-pituitary expression of the prolactin gene in the bone and cartilage of an hPRL-Luc transgenic rat model

Semprini Sabrina , McNeilly Judith R , Ramage Lindsay , Brownstein David G , Salter Donald M , McNeilly Alan , White Michael R H , Davis Julian R E , Mullins John J

Prolactin (PRL) is a peptide hormone produced by the anterior pituitary gland and it is commonly known for its lactogenic and mammotrophic effects. In humans and primates, prolactin is also expressed in extra-pituitary sites where it is associated with numerous biological functions, but its spectrum of expression varies in different species.Hyperprolactinemia-induced osteoporosis is believed to be mediated by hypogonadism, but the expression of the prola...

ea0015oc36 | Thyroid | SFEBES2008

Increased skeletal mineralisation in mice lacking type 2 iodothyronine deiodinase

Bassett JH Duncan , Boyde Alan , Howell Peter GT , Galliford Thomas M , Archanco Marta , St Germain Donald L , Galton Valerie A , Williams Graham R

The prohormone T4 represents the majority of circulating thyroid hormones, whereas 80% of the active hormone T3 is derived from T4 by the actions of the type 1 and type 2 deiodinase enzymes (D1 and D2). Local generation of T3 by D2 regulates ligand supply to the nuclear T3-receptor in pituitary, brown adipose tissue and brain, and this enzyme is also expressed in bone. Hypothyroidism in children causes delayed bone age and growth retardation, whereas thyrotoxicosis in adults c...

ea0015p336 | Thyroid | SFEBES2008

Effects of dietary soy phytoestrogens on thyroid function and insulin resistance in patients with subclinical hypothyroidism: a double blind crossover study

Sathyapalan Thozhukat , Manuchehri Alireza M , Thatcher Natalie J , Clarke Don B , Rigby Alan S , Kilpatrick Eric S , Chapman Tom , Lloyd Anthony S , Atkin Stephen L

Soy phytoestrogens (PE) have been shown to improve insulin resistance and lipids but may adversely affect thyroid function.Objective: To determine the effects of soy PE on thyroid function, insulin resistance and lipid parameters in patients with subclinical hypothyroidism.Design: A randomised, double-blind, crossover study was undertaken involving 60 patients with subclinical hypothyroidism. Patients were randomly assigned to eith...

ea0056oc3.4 | New insights in bone disorders | ECE2018

Renal function change in chronic hypoparathyroidism patients treated with recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and in a historical control cohort treated with standard therapy

Chen Kristina , Rubin Mishaela , Mu Fan , Swallow Elyse , Zhao Jing , Wang Jessie , Krasner Alan , Sherry Nicole , Signorovitch James , Ketteler Markus , Bilezikian John

Standard therapy (ST) for chronic hypoparathyroidism (HPT) includes calcium and active vitamin D supplementation, which can be associated with an increased risk of renal complications. This study compared renal function change, assessed by estimated glomerular filtration rate (eGFR) over 5 years between HPT patients receiving rhPTH1-84 as an adjunct to ST and a historical control cohort without rhPTH1-84. rhPTH1-84-treated HPT patients were selected from two single-arm, long-t...